| Business Summary | | Hyseq,
Inc.
is
engaged
in
the
research
and
development
of
novel
biopharmaceutical
products
from
its
collection
of
proprietary
genes
discovered
using
its
high-throughput
screening-by-hybridization
platform.
The
Company's
activities
have
focused
primarily
on
full-length
gene
sequencing,
patenting,
bioinformatics
and
early
stage
research
activities
to
prioritize
its
therapeutic
protein
candidates.
As
of
March
1,
2001,
the
Company
had
filed
patent
applications
on
more
than
5,600
full-length
gene
sequences.
It
is
advancing
two
molecules,
IL-1Hy1,
with
potential
applications
for
inflammatory
diseases,
and
CD39L4,
with
potential
applications
for
heart
disease,
into
development
in
order
to
generate
data
required
to
file
an
Investigational
New
Drug
application
with
the
Food
and
Drug
Administration.
The
Company's
database
includes
genes
that
encode
chemokines,
growth
factors,
stem
cell
factors,
interferons,
integrins,
hormones,
receptors
and
other
potential
protein
therapeutics
or
drug
targets. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | HYSQ
applies
the
proprietary
DNA
array
technology
of
its
integrated
HyX
genomics
platform
to
develop
gene-based
therapeutic
product
candidates
and
diagnostic
products
and
tests.
For
the
six
months
ended
6/30/01,
revenues
totaled
$11.6
million,
up
from
$5.4
million.
Net
loss
increased
32%
to
$15.1
million.
Revenues
reflect
higher
revenues
earned
from
a
collaboration
with
BASF
Plant
Sciences
GmbH.
Net
loss
reflects
increased
R&D
expenses
due
to
additional
personnel. | More
from
Market Guide: Significant
Developments |
| | | | FY1999 Pay | |
| George Rathmann, 72 Chairman | -- | Ted Love, M.D. Pres,
CEO | -- | Robert Weist, 60 Vice
Chairman | -- | Peter Garcia CFO, Sr. VP | -- | Radoje Drmanac, Ph.D., 42 CSO
and Director | $268K | Dollar amounts are as of 31-Dec-1999 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|